Aernoud Fiolet

85 Colchicine in Stable Coronary Artery Disease AKNOWLEDGEMENTS Dr. Fiolet contributed substantially to the conception and design of the study, the acquisition, investigation, and interpretation of the data; and the design of the article. Drs. Nidorf and Mosterd contributed substantially to the design of the study, interpretation of data, and the draft of the article. Dr. Cornel contributed substantially to the interpretation of the data, the draft of the article, and revisions to the manuscript critically for intellectual content. All authors have seen and approved the final version of the manuscript. The conception of this manuscript was done without financial support from any funding agency or grant. The authors are involved in scientific research supported by grants from the ZonMw (The Netherlands Organisation forHealth Research and Development), the Netherlands Heart Foundation, the Australian National Health and Medical Research Council and generic pharma. JHC takes part in the steering committee of the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). CONFLICTS OF INTEREST The authors have indicated that they have no conflicts of interest regarding the content of this article.